AGTHX
Price
$87.94
Change
+$1.54 (+1.78%)
Updated
Jun 18 closing price
Net Assets
360.63B
ALCCX
Price
$20.25
Change
+$0.43 (+2.17%)
Updated
Jun 18 closing price
Net Assets
2.96B
Interact to see
Advertisement

AGTHX vs ALCCX

AGTHX vs ALCCX Comparison Chart in %
View a ticker or compare two or three
VS
AGTHX vs. ALCCX commentary
Jun 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGTHX is a Hold and ALCCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
AGTHX has more cash in the bank: 361B vs. ALCCX (2.96B). AGTHX pays higher dividends than ALCCX: AGTHX (0.25) vs ALCCX (0.00). AGTHX was incepted earlier than ALCCX: AGTHX (53 years) vs ALCCX (29 years). ALCCX (2.05) is less costly to investors than AGTHX (0.59). ALCCX is a more actively managed with annual turnover of: 75.90 vs. AGTHX (32.00). AGTHX has a lower initial minimum investment than ALCCX: AGTHX (250) vs ALCCX (1000). ALCCX annual gain was more profitable for investors over the last year : 13.26 vs. AGTHX (12.40). AGTHX return over 5 years is better than : 22.23 vs. ALCCX (-17.75).
AGTHXALCCXAGTHX / ALCCX
Total Expense Ratio0.592.0529%
Annual Report Gross Expense Ratio0.592.0529%
Fund Existence53 years29 years-
Gain YTD9.29714.99162%
Front Load6%N/A-
Min. Initial Investment250100025%
Min. Initial Investment IRAN/AN/A-
Net Assets361B2.96B12,192%
Annual Yield % from dividends0.250.00-
Returns for 1 year12.4013.2694%
Returns for 3 years46.9242.01112%
Returns for 5 years22.23-17.75-125%
Returns for 10 years114.4726.64430%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EEMO25.651.36
+5.58%
Invesco S&P Emerging Markets Mom ETF
SPYQ187.283.91
+2.13%
Tradr 2X Long SPY Quarterly ETF
VWO60.771.01
+1.68%
Vanguard FTSE Emerging Markets ETF
BNDC22.070.03
+0.11%
FlexShares Core Select Bond ETF
PPH102.53-1.71
-1.64%
VanEck Pharmaceutical ETF